Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2727-2734

  Stein, Rhona ^a   Govindan, Serengulam V ^b   Hayes, Marianne ^b   Griffiths, Gary L ^b   Hansen, Hans J ^b   Horak, Ivan D ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; IODINE 131; IODINE 131 MONOCLONAL ANTIBODY HMN 14; IODINE 131 PENTETIC ACID MONOCLONAL ANTIBODY HMN 14; IODINE DERIVATIVE; MONOCLONAL ANTIBODY HMN 14; PENTETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17644369265     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2100     Document Type: Article

References (55)

1. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281-96.
2. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73:787-93.
3. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for studies of protein catabolism. FASEB J 1993;7:399-405.
4. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 1995;55: 3132-9.
5. Ali SA, Warren SD, Richter KY, et al. Improving the tumor retention of radioiodinated antibody: arylcarbohydrate adducts. Cancer Res 1990;50:783-8s.
6. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small cell carcinoma of the lung. J Nucl Med 1997;38:391-5.
7. Mattes MJ, Shih LB, Govindan SV, et al. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int J Cancer 1997;71:429-35.
8. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179-88.
9. Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3- pyridinecarboxylate. Cancer Res 1996;56:4970-7.
10. Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 2002; 29:1-11.
11. Govindan SV, Mattes MJ, Stein R, et al. Labeling of monoclonal antibodies with DTPA-appended radioiodinated peptides containing D-amino acids. Bioconjug Chem 1999;10:231-40.
12. Stein R, Govindan SV, Mattes MJ, et al. Targeting human cancer xenografts with mAbs labeled using radioiodinated, DTPA-appended, peptides. Clin Cancer Res 1999;5:3079-87s.
13. Stein R, Govindan SV, Chen S, et al. Successful therapy of a human lung cancer xenograft using mAb RS7 labeled with residualizing radioiodine. Crit Rev Oncol Hemat 2001;39:173-80.
14. Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 2000;60: 4453-60.
15. Shankar S, Vaidyanathan G, Affleck D, Welsh PC, Zalutsky MR. N-succinimidyl 3-[([131])I]iodo-4-phosphonomethylbenzoate ([([131])I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjug Chem 2003;14:331-41.
16. 131I. J Nucl Med 2001;42:967-74.
17. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 2003;63:111-8.
18. Govindan SV, Stein R, Qu Z, et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat 2004;84:173-82.
19. 131I for use in radioimmunotherapy. J Nucl Med 2005;46:153-9.
20. Tsaltas G, Ford CH, Gallant M. Demonstration of monoclonal anti-carcinoembryonic antigen (CEA) antibody internalization by electron microscopy, Western blotting and radioimmunoassay. Anticancer Res 1992;12:2133-42.
21. Ford CH, Tsaltas GC, Osborne PA, Addetia K. Novel flow cytometric analysis of the progress and route of internalization of a monoclonal anti-carcinoembryonic antigen (CEA) antibody. Cytometry 1996;23:228-40.
22. Shih LB, Goldenberg DM, Xuan H, Lu HW, Mattes MJ, Hall TC. Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol Immunother 1994;38:92-8.
23. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-85.
24. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935-45s.
25. McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Immunol 1966;29:185-9.
26. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52: 835-42.
27. Siegel JA, Stabin MG. Absorbed fractions for electrons and β particles in spheres of various sizes. J Nucl Med 1994;35:152-6.
28. Rubin P, Casarett GW. Clinical radiation pathology. Philadelphia: W.B. Saunders; 1968.
29. Beauchemin N, Draber P, Dveksler G, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999;252: 243-9.
30. Hammarstrom S, Olsen A, Teglund S, Baranov V. The nature and expression of the human CEA family. In: Stanners CP, editors. Cell adhesion and communications mediated by the CEA family basic and clinical perspectives. Amsterdam: Harwood Academic Publishers; 1998. p. 1-30.
31. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-81.
32. Gold P, Goldenberg NA. The carcinoembryonic antigen (CEA): past present, and future. McGill J Med 1997;3:46-66.
33. Goldenberg DM, Sharkey RM, Primus F. Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst 1976;57:11-22.
34. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
35. Shively JE, Beatty JD. CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hemat 1985;2:355-99.
36. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5:344-66.
37. Goldenberg DM, Deland FH, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Eng J Med 1978; 298:1384-8.
38. Lane DM, Eagle KF, Begent RH, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br J Cancer 1994;70:521-5.
39. 131I-CC49 in colorectal cancer. Cancer 1994;73:1057-66.
40. 2. J Nucl Med 1996;37:1504-10.
41. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38: 858-70.
42. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997;15:1518-28.
43. 2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer 1998;75:615-9.
44. 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000;6:3095-102.
45. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855-63.
46. Behr TM, Salib AL, Liersch T, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a Phase I clinical study. Clin Cancer Res 1999;5: 3232-42s.
47. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002;94:1373-81.
48. Zalutsky MR, Xu FJ, Yu Y, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 1999;26: 781-90.
49. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1: 553-63.
50. 123I-labeled 80-kilodalton engineered anti-carcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014-21.
51. Adams GP, Shaller CC, Dadachova E, et al. A single treatment of yttrium-90-labeled CHX-A-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004;64:6200-6.
52. Buchegger F, Roth A, Allal A, et al. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Ann NY Acad Sci 2000; 910:263-9.
53. Stein R, Chen S, Reed L, Richel H, Goldenberg DM. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer; effectiveness of dacarbazine. Cancer 2002;94:51-61.
54. DeNardo SJ, Kukis DL, Kroger LA, et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997;94:4000-4.
55. 111In-DTPA- ε-lysine as the primary metabolic and excretory product. Nucl Med Biol 1994;8:1023-34.